ATAI

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) could see increased investor attention as it approaches Phase IIb data for its oral DMT-based therapy VLS-01, according to Jefferies analysts, who highlighted the program's potential to add value to the company's psychedelic medicine pipeline. The analysts wrote that VLS-01's completed Phase IIb enrollment in treatment-resistant depression (TRD) sets up a fourth quarter 2026 topline data readout, which could serve as a potential de-risking event for the program.

ATAI completes dosing in the phase IIb Elumina study of VLS-01 for treatment-resistant depression, with top-line efficacy and safety data due in fourth-quarter 2026.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday that it has completed dosing the final patient in its Phase 2b Elumina clinical trial evaluating investigational therapy VLS-01 for adults with treatment-resistant depression (TRD), with topline results expected in the fourth quarter of 2026. The randomized, double-blind, placebo-controlled trial enrolled 156 patients across multiple centers.

156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized anxiety disorder (GAD) as a potential follow-on indication VLS-01 and BPL-003 (in Phase 3 development for treatment-resistant depression with Breakthrough Therapy Designation) together positioned to address patients across the spectrum of mood and anxiety disorders NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that the last patient has been dosed in Elumina, its Phase 2b clinical trial evaluating VLS-01 in adults living with treatment-resistant depression (TRD). The study randomized 156 patients, with topline data expected in Q4 2026.

ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.

ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.

ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.

ATAI is now a more focused psychedelics biotech. Particularly, BPL-003 is their main bet on TRD's sizeable TAM. BPL-003 has aligned its research with the FDA's feedback and will proceed with a two-study Phase 3 trial. We'll see its topline readouts by early 2029. ATAI also has VLS-01, which gives it a nearer-term Q4 2026 TRD catalyst. EMP-01 adds some optionality in social anxiety disorders as well.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced on Thursday that it will be added to the Russell 2000 Index and the Russell 3000 Index, effective at the open of US markets on June 29, as part of the 2026 Russell indexes reconstitution. The clinical-stage biotechnology company said the inclusion broadens its exposure to institutional investors and index-tracking funds.

AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitution The Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarked Inclusion expands AtaiBeckley's visibility across U.S. equity markets following recent additions to the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes in March 2026 NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will be added to the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. markets on June 29th as part of the first 2026 Russell indexes reconstitution. Approximately $12.2 trillion in assets are benchmarked against the Russell U.S. indexes, making it one of the most widely referenced index systems for institutional investors, index-tracking funds and active investment strategies.